198 related articles for article (PubMed ID: 23242347)
1. The effect of race-ethnicity on the comparative effectiveness of clozapine among Medicaid beneficiaries.
Horvitz-Lennon M; Donohue JM; Lave JR; Alegría M; Normand SL
Psychiatr Serv; 2013 Mar; 64(3):230-7. PubMed ID: 23242347
[TBL] [Abstract][Full Text] [Related]
2. The effect of race-ethnicity and geography on adoption of innovations in the treatment of schizophrenia.
Horvitz-Lennon M; Alegría M; Normand SL
Psychiatr Serv; 2012 Dec; 63(12):1171-7. PubMed ID: 23026838
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with initiation on clozapine and on other antipsychotics among Medicaid enrollees.
Manuel JI; Essock SM; Wu Y; Pangilinan M; Stroup S
Psychiatr Serv; 2012 Nov; 63(11):1146-9. PubMed ID: 23117514
[TBL] [Abstract][Full Text] [Related]
4. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia.
Kuno E; Rothbard AB
Am J Psychiatry; 2002 Apr; 159(4):567-72. PubMed ID: 11925294
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
6. Where You Live Matters: Quality and Racial/Ethnic Disparities in Schizophrenia Care in Four State Medicaid Programs.
Horvitz-Lennon M; Volya R; Garfield R; Donohue JM; Lave JR; Normand SL
Health Serv Res; 2015 Oct; 50(5):1710-29. PubMed ID: 25759240
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations.
Velligan DI; Carroll C; Lage MJ; Fairman K
Psychiatr Serv; 2015 Feb; 66(2):127-33. PubMed ID: 25321616
[TBL] [Abstract][Full Text] [Related]
8. Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia.
Dusetzina SB; Cook BL; Busch AB; Alexander GC; Huskamp HA
Psychiatr Serv; 2013 Jan; 64(1):83-7. PubMed ID: 23280461
[TBL] [Abstract][Full Text] [Related]
9. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine.
Opolka JL; Rascati KL; Brown CM; Gibson PJ
Psychiatr Serv; 2004 Feb; 55(2):151-6. PubMed ID: 14762239
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia.
Stroup TS; Gerhard T; Crystal S; Huang C; Olfson M
Am J Psychiatry; 2016 Feb; 173(2):166-73. PubMed ID: 26541815
[TBL] [Abstract][Full Text] [Related]
11. Disparities in quality of care among publicly insured adults with schizophrenia in four large U.S. states, 2002-2008.
Horvitz-Lennon M; Volya R; Donohue JM; Lave JR; Stein BD; Normand SL
Health Serv Res; 2014 Aug; 49(4):1121-44. PubMed ID: 24628414
[TBL] [Abstract][Full Text] [Related]
12. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
Van Dorn RA; Andel R; Boaz TL; Desmarais SL; Chandler K; Becker MA; Howe A
J Clin Psychiatry; 2011 Apr; 72(4):502-8. PubMed ID: 21527125
[TBL] [Abstract][Full Text] [Related]
13. Racial disparity in the use of atypical antipsychotic medications among veterans.
Copeland LA; Zeber JE; Valenstein M; Blow FC
Am J Psychiatry; 2003 Oct; 160(10):1817-22. PubMed ID: 14514496
[TBL] [Abstract][Full Text] [Related]
14. Racial and ethnic disparities in the treatment of a Medicaid population with schizophrenia.
Horvitz-Lennon M; McGuire TG; Alegria M; Frank RG
Health Serv Res; 2009 Dec; 44(6):2106-22. PubMed ID: 19780855
[TBL] [Abstract][Full Text] [Related]
15. Factors Associated With Off-Label Utilization of Second-Generation Antipsychotics Among Publicly Insured Adults.
Horvitz-Lennon M; Volya R; Hollands S; Zelevinsky K; Mulcahy A; Donohue JM; Normand ST
Psychiatr Serv; 2021 Sep; 72(9):1031-1039. PubMed ID: 34074139
[TBL] [Abstract][Full Text] [Related]
16. Clozapine utilization and outcomes by race in a public mental health system: 1994-2000.
Kelly DL; Dixon LB; Kreyenbuhl JA; Medoff D; Lehman AF; Love RC; Brown CH; Conley RR
J Clin Psychiatry; 2006 Sep; 67(9):1404-11. PubMed ID: 17017827
[TBL] [Abstract][Full Text] [Related]
17. Prescribing of Clozapine and Antipsychotic Polypharmacy for Schizophrenia in a Large Medicaid Program.
Tang Y; Horvitz-Lennon M; Gellad WF; Lave JR; Chang CH; Normand SL; Donohue JM
Psychiatr Serv; 2017 Jun; 68(6):579-586. PubMed ID: 28196460
[TBL] [Abstract][Full Text] [Related]
18. The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.
Meyer JM; Rosenblatt LC; Kim E; Baker RA; Whitehead R
J Clin Psychiatry; 2009 Mar; 70(3):318-25. PubMed ID: 19192469
[TBL] [Abstract][Full Text] [Related]
19. Variation in Psychotropic Medication Prescription for Adults With Schizophrenia in the United States.
Bareis N; Olfson M; Wall M; Stroup TS
Psychiatr Serv; 2022 May; 73(5):492-500. PubMed ID: 34587788
[TBL] [Abstract][Full Text] [Related]
20. Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study.
Arnold JG; Miller AL; Cañive JM; Rosenheck RA; Swartz MS; Mintz J
Psychiatr Serv; 2013 Jun; 64(6):570-8. PubMed ID: 23494108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
